ID   FAK2_HUMAN              Reviewed;        1009 AA.
AC   Q14289; D3DST0; Q13475; Q14290; Q16709; Q6PID4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-OCT-2022, entry version 239.
DE   RecName: Full=Protein-tyrosine kinase 2-beta;
DE            EC=2.7.10.2;
DE   AltName: Full=Calcium-dependent tyrosine kinase;
DE            Short=CADTK;
DE   AltName: Full=Calcium-regulated non-receptor proline-rich tyrosine kinase;
DE   AltName: Full=Cell adhesion kinase beta;
DE            Short=CAK-beta;
DE            Short=CAKB;
DE   AltName: Full=Focal adhesion kinase 2;
DE            Short=FADK 2;
DE   AltName: Full=Proline-rich tyrosine kinase 2;
DE   AltName: Full=Related adhesion focal tyrosine kinase;
DE            Short=RAFTK;
GN   Name=PTK2B; Synonyms=FAK2, PYK2, RAFTK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN REGULATION OF POTASSIUM
RP   CHANNELS; PHOSPHORYLATION OF KCNA2 AND SHC1 AND ACTIVATION OF MAPK1/ERK2,
RP   INTERACTION WITH GRB2, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=7544443; DOI=10.1038/376737a0;
RA   Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M.,
RA   Plowman G.D., Rudy B., Schlessinger J.;
RT   "Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion
RT   channel and MAP kinase functions.";
RL   Nature 376:737-745(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=8838818; DOI=10.1006/geno.1996.0149;
RA   Herzog H., Nicholl J., Hort Y.J., Sutherland G.R., Shine J.;
RT   "Molecular cloning and assignment of FAK2, a novel human focal adhesion
RT   kinase, to 8p11.2-p22 by nonisotopic in situ hybridization.";
RL   Genomics 32:484-486(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=7673154; DOI=10.1074/jbc.270.36.21206;
RA   Sasaki H., Nagura K., Ishino M., Tobioka H., Kotani K., Sasaki T.;
RT   "Cloning and characterization of cell adhesion kinase beta, a novel
RT   protein-tyrosine kinase of the focal adhesion kinase subfamily.";
RL   J. Biol. Chem. 270:21206-21219(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7499242; DOI=10.1074/jbc.270.46.27742;
RA   Avraham S., London R., Fu Y., Ota S., Hiregowdara D., Li J., Jiang S.,
RA   Pasztor L.M., White R.A., Groopman J.E., Avraham H.;
RT   "Identification and characterization of a novel related adhesion focal
RT   tyrosine kinase (RAFTK) from megakaryocytes and brain.";
RL   J. Biol. Chem. 270:27742-27751(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PHOSPHORYLATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Monocyte;
RX   PubMed=9545257; DOI=10.1074/jbc.273.16.9361;
RA   Li X., Hunter D., Morris J., Haskill J.S., Earp H.S.;
RT   "A calcium-dependent tyrosine kinase splice variant in human monocytes.
RT   Activation by a two-stage process involving adherence and a subsequent
RT   intracellular signal.";
RL   J. Biol. Chem. 273:9361-9364(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF SRC AND ACTIVATION OF THE MAP KINASE
RP   SIGNALING CASCADE, INTERACTION WITH SRC, AUTOPHOSPHORYLATION, AND
RP   MUTAGENESIS OF TYR-402.
RX   PubMed=8849729; DOI=10.1038/383547a0;
RA   Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J.;
RT   "A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP
RT   kinase activation.";
RL   Nature 383:547-550(1996).
RN   [10]
RP   FUNCTION IN TNF SIGNALING AND ACTIVATION OF MAPK8/JNK1.
RX   PubMed=8670418; DOI=10.1126/science.273.5276.792;
RA   Tokiwa G., Dikic I., Lev S., Schlessinger J.;
RT   "Activation of Pyk2 by stress signals and coupling with JNK signaling
RT   pathway.";
RL   Science 273:792-794(1996).
RN   [11]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=9422762; DOI=10.1074/jbc.273.2.1003;
RA   Matsuya M., Sasaki H., Aoto H., Mitaka T., Nagura K., Ohba T., Ishino M.,
RA   Takahashi S., Suzuki R., Sasaki T.;
RT   "Cell adhesion kinase beta forms a complex with a new member, Hic-5, of
RT   proteins localized at focal adhesions.";
RL   J. Biol. Chem. 273:1003-1014(1998).
RN   [12]
RP   INTERACTION WITH ASAP2, AND FUNCTION.
RX   PubMed=10022920; DOI=10.1128/mcb.19.3.2338;
RA   Andreev J., Simon J.-P., Sabatini D.D., Kam J., Plowman G., Randazzo P.A.,
RA   Schlessinger J.;
RT   "Identification of a new Pyk2 target protein with Arf-GAP activity.";
RL   Mol. Cell. Biol. 19:2338-2350(1999).
RN   [13]
RP   INTERACTION WITH RB1CC1.
RX   PubMed=10769033; DOI=10.1083/jcb.149.2.423;
RA   Ueda H., Abbi S., Zheng C., Guan J.-L.;
RT   "Suppression of Pyk2 kinase and cellular activities by FIP200.";
RL   J. Cell Biol. 149:423-430(2000).
RN   [14]
RP   PHOSPHORYLATION AT TYR-402, MUTAGENESIS OF PRO-859, AND INTERACTION WITH
RP   NPHP1.
RX   PubMed=11493697; DOI=10.1073/pnas.171269898;
RA   Benzing T., Gerke P., Hoepker K., Hildebrandt F., Kim E., Walz G.;
RT   "Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers
RT   phosphorylation of Pyk2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9784-9789(2001).
RN   [15]
RP   FUNCTION IN ASAP1 PHOSPHORYLATION AND REGULATION OF ASAP1 ACTIVITY, AND
RP   INTERACTION WITH ASAP1.
RX   PubMed=12771146; DOI=10.1074/jbc.m302278200;
RA   Kruljac-Letunic A., Moelleken J., Kallin A., Wieland F., Blaukat A.;
RT   "The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation and
RT   inhibition of the Arf-GTPase-activating protein ASAP1.";
RL   J. Biol. Chem. 278:29560-29570(2003).
RN   [16]
RP   INTERACTION WITH SKAP2, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=12893833; DOI=10.1074/jbc.m213217200;
RA   Takahashi T., Yamashita H., Nagano Y., Nakamura T., Ohmori H., Avraham H.,
RA   Avraham S., Yasuda M., Matsumoto M.;
RT   "Identification and characterization of a novel Pyk2/related adhesion focal
RT   tyrosine kinase-associated protein that inhibits alpha-synuclein
RT   phosphorylation.";
RL   J. Biol. Chem. 278:42225-42233(2003).
RN   [17]
RP   FUNCTION, INTERACTION WITH PDPK1, AND SUBCELLULAR LOCATION.
RX   PubMed=14585963; DOI=10.1128/mcb.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal
RT   adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C.,
RA   Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using mass
RT   spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [19]
RP   FUNCTION IN INTEGRIN SIGNALING AND IN REGULATION OF CELL PROLIFERATION,
RP   CATALYTIC ACTIVITY, AND CHARACTERIZATION OF ISOFORM 2.
RX   PubMed=15050747; DOI=10.1016/j.exphem.2004.01.001;
RA   Dylla S.J., Deyle D.R., Theunissen K., Padurean A.M., Verfaillie C.M.;
RT   "Integrin engagement-induced inhibition of human myelopoiesis is mediated
RT   by proline-rich tyrosine kinase 2 gene products.";
RL   Exp. Hematol. 32:365-374(2004).
RN   [20]
RP   PHOSPHORYLATION AT TYR-402, CATALYTIC ACTIVITY, FUNCTION IN SRC-MEDIATED
RP   PHOSPHORYLATION OF PXN, AND MUTAGENESIS OF LYS-457.
RX   PubMed=15166227; DOI=10.1074/jbc.m313527200;
RA   Park S.Y., Avraham H.K., Avraham S.;
RT   "RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a
RT   Src-independent manner.";
RL   J. Biol. Chem. 279:33315-33322(2004).
RN   [21]
RP   INTERACTION WITH LPXN AND PTPN12, PHOSPHORYLATION AT TYR-402, AND
RP   DEPHOSPHORYLATION BY PTPN12.
RX   PubMed=17329398; DOI=10.1152/ajpcell.00503.2006;
RA   Sahu S.N., Nunez S., Bai G., Gupta A.;
RT   "Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.";
RL   Am. J. Physiol. 292:C2288-C2296(2007).
RN   [22]
RP   FUNCTION IN MIGRATION OF T-LYMPHOCYTES, AND INTERACTION WITH EPHA1; LCK AND
RP   PI3-KINASE.
RX   PubMed=17634955; DOI=10.1002/eji.200737111;
RA   Hjorthaug H.S., Aasheim H.C.;
RT   "Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.";
RL   Eur. J. Immunol. 37:2326-2336(2007).
RN   [23]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND ROLE IN DISEASE.
RX   PubMed=18339875; DOI=10.1158/0008-5472.can-07-5155;
RA   Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C.,
RA   Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L.,
RA   Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N.,
RA   Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M., Vajdos F.;
RT   "Antitumor activity and pharmacology of a selective focal adhesion kinase
RT   inhibitor, PF-562,271.";
RL   Cancer Res. 68:1935-1944(2008).
RN   [24]
RP   FUNCTION IN CELL ADHESION; MIGRATION; PROLIFERATION; REGULATION OF ACTIN
RP   FIBER POLYMERIZATION AND IN ACTIVATION OF SRC; MAPK1/ERK2 AND MAPK3/ERK1,
RP   INTERACTION WITH SRC, SUBCELLULAR LOCATION, AND ROLE IN DISEASE.
RX   PubMed=18765415; DOI=10.1093/carcin/bgn203;
RA   Sun C.K., Man K., Ng K.T., Ho J.W., Lim Z.X., Cheng Q., Lo C.M., Poon R.T.,
RA   Fan S.T.;
RT   "Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and
RT   invasiveness of hepatocellular carcinoma cells through c-Src/ERK
RT   activation.";
RL   Carcinogenesis 29:2096-2105(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; THR-765; SER-839 AND
RP   THR-842, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH RHOU, AND FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON
RP   AND SRC-MEDIATED RHOU PHOSPHORYLATION.
RX   PubMed=18086875; DOI=10.1128/mcb.00201-07;
RA   Ruusala A., Aspenstrom P.;
RT   "The atypical Rho GTPase Wrch1 collaborates with the nonreceptor tyrosine
RT   kinases Pyk2 and Src in regulating cytoskeletal dynamics.";
RL   Mol. Cell. Biol. 28:1802-1814(2008).
RN   [28]
RP   FUNCTION DURING LUNG INJURY, PHOSPHORYLATION BY MYLK, AND INTERACTION WITH
RP   MYLK.
RX   PubMed=18587400; DOI=10.1038/ni.1628;
RA   Xu J., Gao X.-P., Ramchandran R., Zhao Y.-Y., Vogel S.M., Malik A.B.;
RT   "Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in
RT   sepsis-induced lung inflammation by activating beta2 integrins.";
RL   Nat. Immunol. 9:880-886(2008).
RN   [29]
RP   FUNCTION IN REGULATION OF ACTIN CYTOSKELETON REORGANIZATION AND ACTIVATION
RP   OF RHO FAMILY GTPASES, PHOSPHORYLATION AT TYR-402, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH VAV1.
RX   PubMed=19207108; DOI=10.1042/bj20090037;
RA   Gao C., Blystone S.D.;
RT   "A Pyk2-Vav1 complex is recruited to beta3-adhesion sites to initiate Rho
RT   activation.";
RL   Biochem. J. 420:49-56(2009).
RN   [30]
RP   ROLE IN DISEASE, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=19648005; DOI=10.1016/j.bmcl.2009.07.084;
RA   Allen J.G., Lee M.R., Han C.Y., Scherrer J., Flynn S., Boucher C., Zhao H.,
RA   O'Connor A.B., Roveto P., Bauer D., Graceffa R., Richards W.G., Babij P.;
RT   "Identification of small molecule inhibitors of proline-rich tyrosine
RT   kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.";
RL   Bioorg. Med. Chem. Lett. 19:4924-4928(2009).
RN   [31]
RP   FUNCTION IN CELL ADHESION AND SPREADING, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH BCAR1.
RX   PubMed=19086031; DOI=10.1002/jcp.21649;
RA   Rufanova V.A., Alexanian A., Wakatsuki T., Lerner A., Sorokin A.;
RT   "Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and
RT   regulates human glomerular mesangial cell adhesion and spreading.";
RL   J. Cell. Physiol. 219:45-56(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-361; SER-375; SER-399;
RP   TYR-722; SER-762; TYR-819; TYR-834; SER-839; THR-842; TYR-849 AND SER-866,
RP   VARIANT [LARGE SCALE ANALYSIS] THR-838, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [33]
RP   FUNCTION IN IGF1 SIGNALING AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1,
RP   INTERACTION WITH SRC AND GRB2, PHOSPHORYLATION AT TYR-402 AND TYR-881, AND
RP   MUTAGENESIS OF TYR-881.
RX   PubMed=20521079; DOI=10.1007/s00018-010-0411-x;
RA   Shen X., Xi G., Radhakrishnan Y., Clemmons D.R.;
RT   "Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-
RT   dependent mitogenic signaling in vascular smooth muscle cells.";
RL   Cell. Mol. Life Sci. 67:3893-3903(2010).
RN   [34]
RP   FUNCTION IN CELL PROLIFERATION AND REGULATION OF P53/TP53 UBIQUITINATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.m109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating
RT   cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [35]
RP   PHOSPHORYLATION AT TYR-402 AND TYR-580 BY FYN AND LCK.
RX   PubMed=20028775; DOI=10.1189/jlb.0409227;
RA   Collins M., Tremblay M., Chapman N., Curtiss M., Rothman P.B.,
RA   Houtman J.C.;
RT   "The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580
RT   occurs via a distinct mechanism than other receptor systems.";
RL   J. Leukoc. Biol. 87:691-701(2010).
RN   [36]
RP   FUNCTION IN T-CELL RECEPTOR-MEDIATED SIGNALING, AND PHOSPHORYLATION AT
RP   TYR-402 AND TYR-580.
RX   PubMed=20381867; DOI=10.1016/j.molimm.2010.03.009;
RA   Collins M., Bartelt R.R., Houtman J.C.;
RT   "T cell receptor activation leads to two distinct phases of Pyk2 activation
RT   and actin cytoskeletal rearrangement in human T cells.";
RL   Mol. Immunol. 47:1665-1674(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   INTERACTION WITH NPHP1, AND FUNCTION IN PHOSPHORYLATION OF NPHP1.
RX   PubMed=21357692; DOI=10.1074/jbc.m110.165464;
RA   Liebau M.C., Hopker K., Muller R.U., Schmedding I., Zank S., Schairer B.,
RA   Fabretti F., Hohne M., Bartram M.P., Dafinger C., Hackl M., Burst V.,
RA   Habbig S., Zentgraf H., Blaukat A., Walz G., Benzing T., Schermer B.;
RT   "Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of
RT   nephrocystin-1 to control targeting to monocilia.";
RL   J. Biol. Chem. 286:14237-14245(2011).
RN   [39]
RP   FUNCTION IN REORGANIZATION OF CYTOSKELETON; FORMATION OF MEMBRANE RUFFLES
RP   AND CELL MIGRATION, AND ROLE IN DISEASE.
RX   PubMed=21533080; DOI=10.1371/journal.pone.0018878;
RA   Sun C.K., Ng K.T., Lim Z.X., Cheng Q., Lo C.M., Poon R.T., Man K., Wong N.,
RA   Fan S.T.;
RT   "Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of
RT   hepatocellular carcinoma through induction of epithelial to mesenchymal
RT   transition.";
RL   PLoS ONE 6:E18878-E18878(2011).
RN   [40]
RP   REVIEW ON ROLE IN IMMUNITY.
RX   PubMed=15888917; DOI=10.1385/ir:31:3:267;
RA   Ostergaard H.L., Lysechko T.L.;
RT   "Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell
RT   activation and function.";
RL   Immunol. Res. 31:267-282(2005).
RN   [41]
RP   REVIEW ON FUNCTION; SIGNALING; INTERACTION PARTNERS; ACTIVITY REGULATION;
RP   PHOSPHORYLATION, AND ROLE IN DISEASE.
RX   PubMed=20001213; DOI=10.1517/14728220903473194;
RA   Lipinski C.A., Loftus J.C.;
RT   "Targeting Pyk2 for therapeutic intervention.";
RL   Expert Opin. Ther. Targets 14:95-108(2010).
RN   [42]
RP   REVIEW.
RX   PubMed=20332118; DOI=10.1242/jcs.045112;
RA   Schaller M.D.;
RT   "Cellular functions of FAK kinases: insight into molecular mechanisms and
RT   novel functions.";
RL   J. Cell Sci. 123:1007-1013(2010).
RN   [43]
RP   REVIEW ON ROLE IN DISEASE.
RX   PubMed=21196189; DOI=10.2741/3706;
RA   Felty Q.;
RT   "Redox sensitive Pyk2 as a target for therapeutics in breast cancer.";
RL   Front. Biosci. 16:568-577(2011).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375 AND THR-842, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 416-692 IN COMPLEX WITH
RP   PF-2318841, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=18951788; DOI=10.1016/j.bmcl.2008.10.030;
RA   Walker D.P., Bi F.C., Kalgutkar A.S., Bauman J.N., Zhao S.X., Soglia J.R.,
RA   Aspnes G.E., Kung D.W., Klug-McLeod J., Zawistoski M.P., McGlynn M.A.,
RA   Oliver R., Dunn M., Li J.C., Richter D.T., Cooper B.A., Kath J.C.,
RA   Hulford C.A., Autry C.L., Luzzio M.J., Ung E.J., Roberts W.G.,
RA   Bonnette P.C., Buckbinder L., Mistry A., Griffor M.C., Han S.,
RA   Guzman-Perez A.;
RT   "Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase
RT   2 (PYK2): structure-activity relationships and strategies for the
RT   elimination of reactive metabolite formation.";
RL   Bioorg. Med. Chem. Lett. 18:6071-6077(2008).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 861-1009 IN COMPLEX WITH PXN, AND
RP   INTERACTION WITH PXN.
RX   PubMed=19358827; DOI=10.1016/j.bbrc.2009.04.011;
RA   Lulo J., Yuzawa S., Schlessinger J.;
RT   "Crystal structures of free and ligand-bound focal adhesion targeting
RT   domain of Pyk2.";
RL   Biochem. Biophys. Res. Commun. 383:347-352(2009).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 416-692 IN COMPLEX WITH INHIBITOR
RP   P1E, ROLE IN DISEASE, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=19428251; DOI=10.1016/j.bmcl.2009.04.093;
RA   Walker D.P., Zawistoski M.P., McGlynn M.A., Li J.C., Kung D.W.,
RA   Bonnette P.C., Baumann A., Buckbinder L., Houser J.A., Boer J., Mistry A.,
RA   Han S., Xing L., Guzman-Perez A.;
RT   "Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of
RT   proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.";
RL   Bioorg. Med. Chem. Lett. 19:3253-3258(2009).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 416-692 IN COMPLEXES WITH ATP
RP   ANALOG; PF-431396; BIRB796 AND PF-4618433, AND ROLE IN DISEASE.
RX   PubMed=19244237; DOI=10.1074/jbc.m809038200;
RA   Han S., Mistry A., Chang J.S., Cunningham D., Griffor M., Bonnette P.C.,
RA   Wang H., Chrunyk B.A., Aspnes G.E., Walker D.P., Brosius A.D.,
RA   Buckbinder L.;
RT   "Structural characterization of proline-rich tyrosine kinase 2 (PYK2)
RT   reveals a unique (DFG-out) conformation and enables inhibitor design.";
RL   J. Biol. Chem. 284:13193-13201(2009).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 414-692.
RG   Structural genomics consortium (SGC);
RT   "Structure of protein tyrosine kinase 2 beta (PTK2B) kinase domain.";
RL   Submitted (JUL-2011) to the PDB data bank.
RN   [50]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-359; HIS-698; PRO-808; THR-838 AND
RP   LYS-970.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein-tyrosine kinase that regulates
CC       reorganization of the actin cytoskeleton, cell polarization, cell
CC       migration, adhesion, spreading and bone remodeling. Plays a role in the
CC       regulation of the humoral immune response, and is required for normal
CC       levels of marginal B-cells in the spleen and normal migration of
CC       splenic B-cells. Required for normal macrophage polarization and
CC       migration towards sites of inflammation. Regulates cytoskeleton
CC       rearrangement and cell spreading in T-cells, and contributes to the
CC       regulation of T-cell responses. Promotes osteoclastic bone resorption;
CC       this requires both PTK2B/PYK2 and SRC. May inhibit differentiation and
CC       activity of osteoprogenitor cells. Functions in signaling downstream of
CC       integrin and collagen receptors, immune receptors, G-protein coupled
CC       receptors (GPCR), cytokine, chemokine and growth factor receptors, and
CC       mediates responses to cellular stress. Forms multisubunit signaling
CC       complexes with SRC and SRC family members upon activation; this leads
CC       to the phosphorylation of additional tyrosine residues, creating
CC       binding sites for scaffold proteins, effectors and substrates.
CC       Regulates numerous signaling pathways. Promotes activation of
CC       phosphatidylinositol 3-kinase and of the AKT1 signaling cascade.
CC       Promotes activation of NOS3. Regulates production of the cellular
CC       messenger cGMP. Promotes activation of the MAP kinase signaling
CC       cascade, including activation of MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1.
CC       Promotes activation of Rho family GTPases, such as RHOA and RAC1.
CC       Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and
CC       thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and
CC       proteasomal degradation. Acts as a scaffold, binding to both PDPK1 and
CC       SRC, thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373',
CC       and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC family
CC       members, and thereby contributes to the regulation of NMDA receptor ion
CC       channel activity and intracellular Ca(2+) levels. May also regulate
CC       potassium ion transport by phosphorylation of potassium channel
CC       subunits. Phosphorylates SRC; this increases SRC kinase activity.
CC       Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1. Promotes phosphorylation
CC       of ASAP2, RHOU and PXN; this requires both SRC and PTK2/PYK2.
CC       {ECO:0000269|PubMed:10022920, ECO:0000269|PubMed:12771146,
CC       ECO:0000269|PubMed:12893833, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:15050747, ECO:0000269|PubMed:15166227,
CC       ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:18086875,
CC       ECO:0000269|PubMed:18339875, ECO:0000269|PubMed:18587400,
CC       ECO:0000269|PubMed:18765415, ECO:0000269|PubMed:19086031,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:19244237,
CC       ECO:0000269|PubMed:19428251, ECO:0000269|PubMed:19648005,
CC       ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20001213,
CC       ECO:0000269|PubMed:20381867, ECO:0000269|PubMed:20521079,
CC       ECO:0000269|PubMed:21357692, ECO:0000269|PubMed:21533080,
CC       ECO:0000269|PubMed:7544443, ECO:0000269|PubMed:8670418,
CC       ECO:0000269|PubMed:8849729}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:15050747, ECO:0000269|PubMed:15166227,
CC         ECO:0000269|PubMed:18339875, ECO:0000269|PubMed:18951788,
CC         ECO:0000269|PubMed:19428251, ECO:0000269|PubMed:19648005};
CC   -!- ACTIVITY REGULATION: Activated in response to stimuli that lead to
CC       increased intracellular Ca(2+) levels; this activation is indirect and
CC       may be mediated by calcium-mediated production of reactive oxygen
CC       species (ROS). Activated by autophosphorylation at Tyr-402; this
CC       creates a binding site for SRC family kinases and leads to
CC       phosphorylation at additional tyrosine residues. Phosphorylation at
CC       Tyr-402, Tyr-579 and Tyr-580 is required for optimal kinase activity.
CC       Inhibited by PF-562,271, BIRB796, PF-4618433 and by PF-431396, PF-
CC       2318841 and their derivatives. Inhibited by sulfoximine-substituted
CC       trifluoromethylpyrimidines. Inhibited by 4-amino and 5-aryl substituted
CC       pyridinone compounds. {ECO:0000269|PubMed:18339875,
CC       ECO:0000269|PubMed:18951788, ECO:0000269|PubMed:19428251,
CC       ECO:0000269|PubMed:19648005}.
CC   -!- SUBUNIT: Homodimer, or homooligomer. Interacts with SIRPA and SH2D3C.
CC       Interacts with ARHGAP10. Interacts with DLG4 (By similarity). Interacts
CC       with KCNA2 (By similarity). Interacts with NPHP1, ASAP1, ASAP2,
CC       ARHGAP26, SKAP2 and TGFB1I1. The Tyr-402 phosphorylated form interacts
CC       with SRC (via SH2 domain) and SRC family members. Forms a signaling
CC       complex with EPHA1, LCK and phosphatidylinositol 3-kinase; upon
CC       activation by EFNA1. Interacts with GRB2 (via SH2 domain). Interacts
CC       with P53/TP53 and MDM2. Interacts with MYLK. Interacts with BCAR1.
CC       Interacts with PDPK1. Interacts (hypophosphorylated) with PXN.
CC       Interacts with RB1CC1. Interacts with RHOU. Interacts with VAV1.
CC       Interacts with LPXN and PTPN12. {ECO:0000250|UniProtKB:P70600,
CC       ECO:0000250|UniProtKB:Q9QVP9, ECO:0000269|PubMed:10022920,
CC       ECO:0000269|PubMed:10769033, ECO:0000269|PubMed:11493697,
CC       ECO:0000269|PubMed:12771146, ECO:0000269|PubMed:12893833,
CC       ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:17329398,
CC       ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:18086875,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:18765415,
CC       ECO:0000269|PubMed:18951788, ECO:0000269|PubMed:19086031,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:19358827,
CC       ECO:0000269|PubMed:19428251, ECO:0000269|PubMed:20521079,
CC       ECO:0000269|PubMed:21357692, ECO:0000269|PubMed:7544443,
CC       ECO:0000269|PubMed:8849729, ECO:0000269|PubMed:9422762}.
CC   -!- INTERACTION:
CC       Q14289; P05067: APP; NbExp=3; IntAct=EBI-298640, EBI-77613;
CC       Q14289; P06241: FYN; NbExp=5; IntAct=EBI-298640, EBI-515315;
CC       Q14289; O15259: NPHP1; NbExp=2; IntAct=EBI-298640, EBI-953828;
CC       Q14289; O75161: NPHP4; NbExp=2; IntAct=EBI-298640, EBI-4281852;
CC       Q14289; Q7L0Q8: RHOU; NbExp=4; IntAct=EBI-298640, EBI-1638043;
CC       Q14289; P12931: SRC; NbExp=3; IntAct=EBI-298640, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, perinuclear region. Cell
CC       membrane; Peripheral membrane protein; Cytoplasmic side. Cell junction,
CC       focal adhesion. Cell projection, lamellipodium. Cytoplasm, cell cortex.
CC       Nucleus. Note=Interaction with NPHP1 induces the membrane-association
CC       of the kinase. Colocalizes with integrins at the cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14289-1; Sequence=Displayed;
CC       Name=2; Synonyms=PYK2H;
CC         IsoId=Q14289-2; Sequence=VSP_004981;
CC   -!- TISSUE SPECIFICITY: Most abundant in the brain, with highest levels in
CC       amygdala and hippocampus. Low levels in kidney (at protein level). Also
CC       expressed in spleen and lymphocytes. {ECO:0000269|PubMed:7544443,
CC       ECO:0000269|PubMed:9545257}.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to various stimuli
CC       that elevate the intracellular calcium concentration; this activation
CC       is indirect and may be mediated by production of reactive oxygen
CC       species (ROS). Tyr-402 is the major autophosphorylation site, but other
CC       kinases can also phosphorylate Tyr-402. Autophosphorylation occurs in
CC       trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine
CC       residues on the other subunit. Phosphorylation at Tyr-402 promotes
CC       interaction with SRC and SRC family members, leading to phosphorylation
CC       at Tyr-579; Tyr-580 and Tyr-881. Phosphorylation at Tyr-881 is
CC       important for interaction with GRB2. Phosphorylated on tyrosine
CC       residues upon activation of FGR and PKC. Recruitment by NPHP1 to cell
CC       matrix adhesions initiates Tyr-402 phosphorylation. In monocytes,
CC       adherence to substrata is required for tyrosine phosphorylation and
CC       kinase activation. Angiotensin II, thapsigargin and L-alpha-
CC       lysophosphatidic acid (LPA) also induce autophosphorylation and
CC       increase kinase activity. Phosphorylation by MYLK promotes ITGB2
CC       activation and is thus essential to trigger neutrophil transmigration
CC       during lung injury. Dephosphorylated by PTPN12.
CC       {ECO:0000269|PubMed:11493697, ECO:0000269|PubMed:15166227,
CC       ECO:0000269|PubMed:17329398, ECO:0000269|PubMed:18587400,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:20028775,
CC       ECO:0000269|PubMed:20381867, ECO:0000269|PubMed:20521079,
CC       ECO:0000269|PubMed:9545257}.
CC   -!- DISEASE: Note=Aberrant PTK2B/PYK2 expression may play a role in cancer
CC       cell proliferation, migration and invasion, in tumor formation and
CC       metastasis. Elevated PTK2B/PYK2 expression is seen in gliomas,
CC       hepatocellular carcinoma, lung cancer and breast cancer.
CC   -!- MISCELLANEOUS: Promotes bone resorption, and thus PTK2B/PYK2 inhibitors
CC       might be used to treat osteoporosis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. FAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U33284; AAC50203.1; -; mRNA.
DR   EMBL; L49207; AAB47217.1; -; mRNA.
DR   EMBL; D45853; BAA08289.1; -; mRNA.
DR   EMBL; U43522; AAC05330.1; -; mRNA.
DR   EMBL; S80542; AAB35701.1; -; mRNA.
DR   EMBL; AF311103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471080; EAW63553.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63555.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63556.1; -; Genomic_DNA.
DR   EMBL; BC036651; AAH36651.1; -; mRNA.
DR   EMBL; BC042599; AAH42599.1; -; mRNA.
DR   CCDS; CCDS6057.1; -. [Q14289-1]
DR   CCDS; CCDS6058.1; -. [Q14289-2]
DR   PIR; S60248; S60248.
DR   RefSeq; NP_004094.3; NM_004103.4. [Q14289-1]
DR   RefSeq; NP_775266.1; NM_173174.2. [Q14289-1]
DR   RefSeq; NP_775267.1; NM_173175.2. [Q14289-2]
DR   RefSeq; NP_775268.1; NM_173176.2. [Q14289-1]
DR   RefSeq; XP_005273504.1; XM_005273447.4. [Q14289-1]
DR   RefSeq; XP_011542743.1; XM_011544441.2. [Q14289-1]
DR   RefSeq; XP_016868703.1; XM_017013214.1. [Q14289-1]
DR   PDB; 2LK4; NMR; -; A=871-1005.
DR   PDB; 3CC6; X-ray; 1.60 A; A=414-692.
DR   PDB; 3ET7; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZO; X-ray; 2.20 A; A=416-692.
DR   PDB; 3FZP; X-ray; 2.10 A; A=416-692.
DR   PDB; 3FZR; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZS; X-ray; 1.75 A; A=416-692.
DR   PDB; 3FZT; X-ray; 1.95 A; A=416-692.
DR   PDB; 3GM1; X-ray; 2.95 A; A/B=861-1009.
DR   PDB; 3GM2; X-ray; 2.71 A; A=861-1009.
DR   PDB; 3GM3; X-ray; 2.60 A; A=861-1009.
DR   PDB; 3H3C; X-ray; 2.00 A; A=416-692.
DR   PDB; 3U3F; X-ray; 3.10 A; A/B/C/D=871-1005.
DR   PDB; 4EKU; X-ray; 3.25 A; A=21-409.
DR   PDB; 4H1J; X-ray; 2.00 A; A=416-692.
DR   PDB; 4H1M; X-ray; 1.99 A; A=416-692.
DR   PDB; 4R32; X-ray; 3.50 A; A=871-1005.
DR   PDB; 4XEF; X-ray; 2.50 A; A/D=871-1005.
DR   PDB; 4XEK; X-ray; 1.79 A; A=871-1005.
DR   PDB; 4XEV; X-ray; 2.01 A; A/D=871-1005.
DR   PDB; 5TO8; X-ray; 1.98 A; A=414-692.
DR   PDB; 5TOB; X-ray; 2.12 A; A=414-692.
DR   PDB; 6LF3; X-ray; 3.20 A; A/B/C/D/E/F=790-839.
DR   PDBsum; 2LK4; -.
DR   PDBsum; 3CC6; -.
DR   PDBsum; 3ET7; -.
DR   PDBsum; 3FZO; -.
DR   PDBsum; 3FZP; -.
DR   PDBsum; 3FZR; -.
DR   PDBsum; 3FZS; -.
DR   PDBsum; 3FZT; -.
DR   PDBsum; 3GM1; -.
DR   PDBsum; 3GM2; -.
DR   PDBsum; 3GM3; -.
DR   PDBsum; 3H3C; -.
DR   PDBsum; 3U3F; -.
DR   PDBsum; 4EKU; -.
DR   PDBsum; 4H1J; -.
DR   PDBsum; 4H1M; -.
DR   PDBsum; 4R32; -.
DR   PDBsum; 4XEF; -.
DR   PDBsum; 4XEK; -.
DR   PDBsum; 4XEV; -.
DR   PDBsum; 5TO8; -.
DR   PDBsum; 5TOB; -.
DR   PDBsum; 6LF3; -.
DR   AlphaFoldDB; Q14289; -.
DR   BMRB; Q14289; -.
DR   SMR; Q14289; -.
DR   BioGRID; 108480; 68.
DR   CORUM; Q14289; -.
DR   ELM; Q14289; -.
DR   IntAct; Q14289; 43.
DR   MINT; Q14289; -.
DR   STRING; 9606.ENSP00000380638; -.
DR   BindingDB; Q14289; -.
DR   ChEMBL; CHEMBL5469; -.
DR   DrugBank; DB08341; 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide.
DR   DrugBank; DB11817; Baricitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB01097; Leflunomide.
DR   DrugCentral; Q14289; -.
DR   GuidetoPHARMACOLOGY; 2181; -.
DR   iPTMnet; Q14289; -.
DR   PhosphoSitePlus; Q14289; -.
DR   SwissPalm; Q14289; -.
DR   BioMuta; PTK2B; -.
DR   DMDM; 3183003; -.
DR   CPTAC; CPTAC-1791; -.
DR   EPD; Q14289; -.
DR   jPOST; Q14289; -.
DR   MassIVE; Q14289; -.
DR   MaxQB; Q14289; -.
DR   PaxDb; Q14289; -.
DR   PeptideAtlas; Q14289; -.
DR   PRIDE; Q14289; -.
DR   ProteomicsDB; 59955; -. [Q14289-1]
DR   ProteomicsDB; 59956; -. [Q14289-2]
DR   TopDownProteomics; Q14289-2; -. [Q14289-2]
DR   Antibodypedia; 3551; 1056 antibodies from 43 providers.
DR   DNASU; 2185; -.
DR   Ensembl; ENST00000346049.10; ENSP00000332816.6; ENSG00000120899.18. [Q14289-1]
DR   Ensembl; ENST00000397501.5; ENSP00000380638.1; ENSG00000120899.18. [Q14289-1]
DR   Ensembl; ENST00000420218.3; ENSP00000391995.2; ENSG00000120899.18. [Q14289-2]
DR   Ensembl; ENST00000517339.5; ENSP00000427931.1; ENSG00000120899.18. [Q14289-2]
DR   GeneID; 2185; -.
DR   KEGG; hsa:2185; -.
DR   MANE-Select; ENST00000346049.10; ENSP00000332816.6; NM_173176.3; NP_775268.1.
DR   UCSC; uc003xfn.3; human. [Q14289-1]
DR   CTD; 2185; -.
DR   DisGeNET; 2185; -.
DR   GeneCards; PTK2B; -.
DR   HGNC; HGNC:9612; PTK2B.
DR   HPA; ENSG00000120899; Tissue enhanced (bone marrow, brain).
DR   MIM; 601212; gene.
DR   neXtProt; NX_Q14289; -.
DR   NIAGADS; ENSG00000120899; -.
DR   OpenTargets; ENSG00000120899; -.
DR   PharmGKB; PA33956; -.
DR   VEuPathDB; HostDB:ENSG00000120899; -.
DR   eggNOG; KOG4257; Eukaryota.
DR   GeneTree; ENSGT00940000157269; -.
DR   HOGENOM; CLU_002646_0_1_1; -.
DR   InParanoid; Q14289; -.
DR   OMA; IMELYSY; -.
DR   OrthoDB; 43729at2759; -.
DR   PhylomeDB; Q14289; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q14289; -.
DR   Reactome; R-HSA-391160; Signal regulatory protein family interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   SignaLink; Q14289; -.
DR   SIGNOR; Q14289; -.
DR   BioGRID-ORCS; 2185; 19 hits in 1115 CRISPR screens.
DR   ChiTaRS; PTK2B; human.
DR   EvolutionaryTrace; Q14289; -.
DR   GeneWiki; PTK2B; -.
DR   GenomeRNAi; 2185; -.
DR   Pharos; Q14289; Tclin.
DR   PRO; PR:Q14289; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q14289; protein.
DR   Bgee; ENSG00000120899; Expressed in right hemisphere of cerebellum and 163 other tissues.
DR   ExpressionAtlas; Q14289; baseline and differential.
DR   Genevisible; Q14289; HS.
DR   GO; GO:0097440; C:apical dendrite; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0044297; C:cell body; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043423; F:3-phosphoinositide-dependent protein kinase binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IMP:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IPI:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0090630; P:activation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0042976; P:activation of Janus kinase activity; IMP:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0043534; P:blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0086100; P:endothelin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0048041; P:focal adhesion assembly; IEA:Ensembl.
DR   GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0060292; P:long-term synaptic depression; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043267; P:negative regulation of potassium ion transport; IDA:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:CACAO.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:2000538; P:positive regulation of B cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0050848; P:regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0010752; P:regulation of cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0032960; P:regulation of inositol trisphosphate biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0010758; P:regulation of macrophage chemotaxis; ISS:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; TAS:ARUK-UCL.
DR   GO; GO:2000058; P:regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0043157; P:response to cation stress; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009725; P:response to hormone; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0035902; P:response to immobilization stress; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0010226; P:response to lithium ion; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0007172; P:signal complex assembly; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   CDD; cd13190; FERM_C_FAK1; 1.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR041390; FADK_N.
DR   InterPro; IPR041784; FAK1/PYK2_FERM_C.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_sf.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR036137; Focal_adhe_kin_target_dom_sf.
DR   InterPro; IPR005189; Focal_adhesion_kin_target_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR030610; PTK2B.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR24418:SF94; PTHR24418:SF94; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF18038; FERM_N_2; 1.
DR   Pfam; PF03623; Focal_AT; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF68993; SSF68993; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis;
KW   ATP-binding; Cell junction; Cell membrane; Cell projection; Cytoplasm;
KW   Immunity; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..1009
FT                   /note="Protein-tyrosine kinase 2-beta"
FT                   /id="PRO_0000088081"
FT   DOMAIN          39..359
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   DOMAIN          425..683
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          701..725
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          801..1009
FT                   /note="Interaction with TGFB1I1"
FT                   /evidence="ECO:0000250"
FT   REGION          868..1009
FT                   /note="Focal adhesion targeting (FAT)"
FT   COMPBIAS        708..725
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        549
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         431..439
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19244237,
FT                   ECO:0007744|PDB:3FZP"
FT   BINDING         457
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19244237,
FT                   ECO:0007744|PDB:3FZP"
FT   BINDING         503..509
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19244237,
FT                   ECO:0007744|PDB:3FZP"
FT   MOD_RES         361
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         399
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         402
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11493697,
FT                   ECO:0000269|PubMed:15166227, ECO:0000269|PubMed:17329398,
FT                   ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:20028775,
FT                   ECO:0000269|PubMed:20381867, ECO:0000269|PubMed:20521079"
FT   MOD_RES         579
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QVP9"
FT   MOD_RES         580
FT                   /note="Phosphotyrosine; by SRC, FYN and LCK"
FT                   /evidence="ECO:0000269|PubMed:20028775,
FT                   ECO:0000269|PubMed:20381867"
FT   MOD_RES         722
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         762
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         765
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         819
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         834
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         839
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         842
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         849
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         866
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         881
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:20521079"
FT   VAR_SEQ         739..780
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9545257"
FT                   /id="VSP_004981"
FT   VARIANT         359
FT                   /note="Q -> E (in dbSNP:rs56175011)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041687"
FT   VARIANT         698
FT                   /note="R -> H (in dbSNP:rs35174236)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041688"
FT   VARIANT         808
FT                   /note="L -> P (in dbSNP:rs55747955)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041689"
FT   VARIANT         838
FT                   /note="K -> T (in dbSNP:rs751019)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0007744|PubMed:19369195"
FT                   /id="VAR_020284"
FT   VARIANT         970
FT                   /note="E -> K (in dbSNP:rs56263944)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041690"
FT   MUTAGEN         402
FT                   /note="Y->F: Abolishes autophosphorylation. Abolishes
FT                   interaction with SRC."
FT                   /evidence="ECO:0000269|PubMed:8849729"
FT   MUTAGEN         457
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15166227"
FT   MUTAGEN         859
FT                   /note="P->A: Loss of interaction with NPHP1."
FT                   /evidence="ECO:0000269|PubMed:11493697"
FT   MUTAGEN         881
FT                   /note="Y->F: Loss of phosphorylation site. Strongly reduced
FT                   interaction with GRB2."
FT                   /evidence="ECO:0000269|PubMed:20521079"
FT   CONFLICT        23
FT                   /note="A -> G (in Ref. 3; BAA08289/AAC05330)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        256
FT                   /note="G -> P (in Ref. 2; AAB47217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        435
FT                   /note="F -> L (in Ref. 3; AAC05330)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        780
FT                   /note="R -> G (in Ref. 2; AAB47217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        985
FT                   /note="V -> M (in Ref. 8; AAH36651)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..37
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          38..45
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           52..54
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          55..62
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           67..76
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            77..80
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           87..89
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          90..99
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           111..117
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            119..121
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           124..126
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          127..133
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            138..140
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           141..144
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           148..165
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            166..169
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           172..186
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            187..189
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           194..196
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           198..207
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           210..212
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           216..221
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           224..238
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           243..254
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          263..273
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          277..282
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          285..289
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          297..300
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           302..304
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          310..313
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   TURN            314..316
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          317..322
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          331..336
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           338..355
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   STRAND          356..360
FT                   /evidence="ECO:0007829|PDB:4EKU"
FT   HELIX           422..424
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          425..433
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          435..445
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          447..449
FT                   /evidence="ECO:0007829|PDB:3FZR"
FT   STRAND          451..458
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          461..463
FT                   /evidence="ECO:0007829|PDB:3FZO"
FT   HELIX           465..481
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          489..493
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          495..497
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          499..503
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           510..517
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   TURN            518..520
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           523..542
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          546..548
FT                   /evidence="ECO:0007829|PDB:5TO8"
FT   HELIX           552..554
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          555..559
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   STRAND          562..565
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           570..572
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           589..591
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           594..599
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           604..619
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   TURN            620..622
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   TURN            625..628
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           631..633
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           634..640
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           652..661
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           666..668
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           672..691
FT                   /evidence="ECO:0007829|PDB:3CC6"
FT   HELIX           879..897
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   HELIX           898..900
FT                   /evidence="ECO:0007829|PDB:3GM3"
FT   HELIX           903..905
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   HELIX           906..927
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   HELIX           928..930
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   HELIX           933..962
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   TURN            963..965
FT                   /evidence="ECO:0007829|PDB:4XEK"
FT   HELIX           969..1004
FT                   /evidence="ECO:0007829|PDB:4XEK"
SQ   SEQUENCE   1009 AA;  115875 MW;  420B21046274E7C2 CRC64;
     MSGVSEPLSR VKLGTLRRPE GPAEPMVVVP VDVEKEDVRI LKVCFYSNSF NPGKNFKLVK
     CTVQTEIREI ITSILLSGRI GPNIRLAECY GLRLKHMKSD EIHWLHPQMT VGEVQDKYEC
     LHVEAEWRYD LQIRYLPEDF MESLKEDRTT LLYFYQQLRN DYMQRYASKV SEGMALQLGC
     LELRRFFKDM PHNALDKKSN FELLEKEVGL DLFFPKQMQE NLKPKQFRKM IQQTFQQYAS
     LREEECVMKF FNTLAGFANI DQETYRCELI QGWNITVDLV IGPKGIRQLT SQDAKPTCLA
     EFKQIRSIRC LPLEEGQAVL QLGIEGAPQA LSIKTSSLAE AENMADLIDG YCRLQGEHQG
     SLIIHPRKDG EKRNSLPQIP MLNLEARRSH LSESCSIESD IYAEIPDETL RRPGGPQYGI
     AREDVVLNRI LGEGFFGEVY EGVYTNHKGE KINVAVKTCK KDCTLDNKEK FMSEAVIMKN
     LDHPHIVKLI GIIEEEPTWI IMELYPYGEL GHYLERNKNS LKVLTLVLYS LQICKAMAYL
     ESINCVHRDI AVRNILVASP ECVKLGDFGL SRYIEDEDYY KASVTRLPIK WMSPESINFR
     RFTTASDVWM FAVCMWEILS FGKQPFFWLE NKDVIGVLEK GDRLPKPDLC PPVLYTLMTR
     CWDYDPSDRP RFTELVCSLS DVYQMEKDIA MEQERNARYR TPKILEPTAF QEPPPKPSRP
     KYRPPPQTNL LAPKLQFQVP EGLCASSPTL TSPMEYPSPV NSLHTPPLHR HNVFKRHSMR
     EEDFIQPSSR EEAQQLWEAE KVKMRQILDK QQKQMVEDYQ WLRQEEKSLD PMVYMNDKSP
     LTPEKEVGYL EFTGPPQKPP RLGAQSIQPT ANLDRTDDLV YLNVMELVRA VLELKNELCQ
     LPPEGYVVVV KNVGLTLRKL IGSVDDLLPS LPSSSRTEIE GTQKLLNKDL AELINKMRLA
     QQNAVTSLSE ECKRQMLTAS HTLAVDAKNL LDAVDQAKVL ANLAHPPAE
//
